Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

A Cyclic Pentamethinium Salt Induces Cancer Cell Cytotoxicity through Mitochondrial Disintegration and Metabolic Collapse.

Krejcir R, Krcova L, Zatloukalova P, Briza T, Coates PJ, Sterba M, Muller P, Kralova J, Martasek P, Kral V, Vojtesek B.

Int J Mol Sci. 2019 Aug 28;20(17). pii: E4208. doi: 10.3390/ijms20174208.

2.

In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.

Pokorna Z, Jirkovsky E, Hlavackova M, Jansova H, Jirkovska A, Lencova-Popelova O, Brazdova P, Kubes J, Sotakova-Kasparova D, Mazurova Y, Adamcova M, Vostatkova L, Holzerova K, Kolar F, Simunek T, Sterba M.

Clin Sci (Lond). 2019 Aug 27;133(16):1827-1844. doi: 10.1042/CS20190139. Print 2019 Aug 30.

PMID:
31409729
3.

Effect of impact velocity and ligament mechanical properties on lumbar spine injuries in posterior-anterior impact loading conditions: a finite element study.

Sterba M, Aubin CÉ, Wagnac E, Fradet L, Arnoux PJ.

Med Biol Eng Comput. 2019 Jun;57(6):1381-1392. doi: 10.1007/s11517-019-01964-5. Epub 2019 Mar 4.

PMID:
30828778
4.

Biomechanical analysis of spino-pelvic postural configurations in spondylolysis subjected to various sport-related dynamic loading conditions.

Sterba M, Arnoux PJ, Labelle H, Warner WC, Aubin CÉ.

Eur Spine J. 2018 Aug;27(8):2044-2052. doi: 10.1007/s00586-018-5667-0. Epub 2018 Jun 20.

PMID:
29926211
5.

Comprehensive review of cardiovascular toxicity of drugs and related agents.

Mladěnka P, Applová L, Patočka J, Costa VM, Remiao F, Pourová J, Mladěnka A, Karlíčková J, Jahodář L, Vopršalová M, Varner KJ, Štěrba M; TOX-OER and CARDIOTOX Hradec Králové Researchers and Collaborators.

Med Res Rev. 2018 Jul;38(4):1332-1403. doi: 10.1002/med.21476. Epub 2018 Jan 5. Review.

6.

Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart.

Jirkovský E, Jirkovská A, Bureš J, Chládek J, Lenčová O, Stariat J, Pokorná Z, Karabanovich G, Roh J, Brázdová P, Šimůnek T, Kovaříková P, Štěrba M.

J Pharmacol Exp Ther. 2018 Mar;364(3):433-446. doi: 10.1124/jpet.117.244848. Epub 2017 Dec 22.

PMID:
29273587
7.

Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.

Bures J, Jirkovska A, Sestak V, Jansova H, Karabanovich G, Roh J, Sterba M, Simunek T, Kovarikova P.

Toxicology. 2017 Dec 1;392:1-10. doi: 10.1016/j.tox.2017.09.012. Epub 2017 Sep 21.

PMID:
28941780
8.

Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?

Lenčová-Popelová O, Jansová H, Jirkovský E, Bureš J, Jirkovská-Vávrová A, Mazurová Y, Reimerová P, Vostatková L, Adamcová M, Hroch M, Pokorná Z, Kovaříková P, Šimůnek T, Štěrba M.

Toxicology. 2016 Nov 30;372:52-63. doi: 10.1016/j.tox.2016.11.002. Epub 2016 Nov 2.

PMID:
27816693
9.

Corrigendum to: "Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model" [Exp. Cell Res. 339 2 (2015) 174-186].

Lenčo J, Lenčová-Popelová O, Link M, Jirkovská A, Tambor V, Potůčková E, Stulík J, Šimůnek T, Štěrba M.

Exp Cell Res. 2016 May 1;343(2):267. doi: 10.1016/j.yexcr.2016.02.007. Epub 2016 Apr 4. No abstract available.

PMID:
27155561
10.

Cardiac troponins--Translational biomarkers in cardiology: Theory and practice of cardiac troponin high-sensitivity assays.

Adamcova M, Popelova-Lencova O, Jirkovsky E, Simko F, Gersl V, Sterba M.

Biofactors. 2016 Mar-Apr;42(2):133-48. doi: 10.1002/biof.1261. Epub 2016 Feb 15. Review.

PMID:
26876101
11.

Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.

Lenčová-Popelová O, Jirkovský E, Jansová H, Jirkovská-Vávrová A, Vostatková-Tichotová L, Mazurová Y, Adamcová M, Chládek J, Hroch M, Pokorná Z, Geršl V, Šimůnek T, Štěrba M.

J Mol Cell Cardiol. 2016 Feb;91:92-103. doi: 10.1016/j.yjmcc.2015.12.021. Epub 2015 Dec 23.

PMID:
26724189
12.

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.

Sestak V, Stariat J, Cermanova J, Potuckova E, Chladek J, Roh J, Bures J, Jansova H, Prusa P, Sterba M, Micuda S, Simunek T, Kalinowski DS, Richardson DR, Kovarikova P.

Oncotarget. 2015 Dec 15;6(40):42411-28. doi: 10.18632/oncotarget.6389.

13.

Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model.

Lenčo J, Lenčová-Popelová O, Link M, Jirkovská A, Tambor V, Potůčková E, Stulík J, Šimůnek T, Štěrba M.

Exp Cell Res. 2015 Dec 10;339(2):174-86. doi: 10.1016/j.yexcr.2015.10.020. Epub 2015 Nov 5. Erratum in: Exp Cell Res. 2016 May 1;343 (2):267.

PMID:
26515555
14.

Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value.

Adamcova M, Lencova-Popelova O, Jirkovsky E, Mazurova Y, Palicka V, Simko F, Gersl V, Sterba M.

Int J Cardiol. 2015 Dec 15;201:358-67. doi: 10.1016/j.ijcard.2015.07.103. Epub 2015 Aug 4.

PMID:
26310978
15.

Safety and efficacy compared between irinotecan-loaded microspheres HepaSphere and DC bead in a model of VX2 liver metastases in the rabbit.

Namur J, Pascale F, Maeda N, Sterba M, Ghegediban SH, Verret V, Paci A, Seck A, Osuga K, Wassef M, Reb P, Laurent A.

J Vasc Interv Radiol. 2015 Jul;26(7):1067-1075.e3. doi: 10.1016/j.jvir.2015.03.014. Epub 2015 May 4.

PMID:
25952641
16.

Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.

Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, Walker A, Bailey MJ, Johnson B, Millis D, Ding G, Peake S, Wong H, Thomas J, Smith K, Forbes L, Hardie M, Micallef S, Fraser JF; ProGUARD Study Investigators; ANZICS Clinical Trials Group.

Am J Respir Crit Care Med. 2014 Nov 15;190(10):1102-10. doi: 10.1164/rccm.201408-1483OC.

PMID:
25295709
17.

Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats.

Cermanova J, Kadova Z, Dolezelova E, Zagorova M, Safka V, Hroch M, Laho T, Holeckova M, Mokry J, Kovarikova P, Bures J, Sterba M, Micuda S.

Shock. 2014 Oct;42(4):372-9. doi: 10.1097/SHK.0000000000000210.

PMID:
25140599
18.

Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up.

Lenčová-Popelová O, Jirkovský E, Mazurová Y, Lenčo J, Adamcová M, Šimůnek T, Geršl V, Štěrba M.

PLoS One. 2014 May 7;9(5):e96055. doi: 10.1371/journal.pone.0096055. eCollection 2014.

19.

Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Vavrova A, Jansova H, Mackova E, Machacek M, Haskova P, Tichotova L, Sterba M, Simunek T.

PLoS One. 2013 Oct 7;8(10):e76676. doi: 10.1371/journal.pone.0076676. eCollection 2013.

20.

Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.

Jirkovský E, Lenčová-Popelová O, Hroch M, Adamcová M, Mazurová Y, Vávrová J, Mičuda S, Šimůnek T, Geršl V, Štěrba M.

Toxicology. 2013 Sep 15;311(3):191-204. doi: 10.1016/j.tox.2013.06.012. Epub 2013 Jul 4.

PMID:
23831762
21.

Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.

Jirkovsky E, Popelová O, Kriváková-Stanková P, Vávrová A, Hroch M, Hasková P, Brcáková-Dolezelová E, Micuda S, Adamcová M, Simůnek T, Cervinková Z, Gersl V, Sterba M.

J Pharmacol Exp Ther. 2012 Nov;343(2):468-78. doi: 10.1124/jpet.112.198358. Epub 2012 Aug 22.

PMID:
22915767
22.

Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts.

Neckář J, Boudíková A, Mandíková P, Stěrba M, Popelová O, Mikšík I, Dabrowská L, Mráz J, Geršl V, Kolář F.

Can J Physiol Pharmacol. 2012 Sep;90(9):1303-10. doi: 10.1139/y2012-096. Epub 2012 Aug 22.

PMID:
22913659
23.

Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Stěrba M, Popelová O, Vávrová A, Jirkovský E, Kovaříková P, Geršl V, Simůnek T.

Antioxid Redox Signal. 2013 Mar 10;18(8):899-929. doi: 10.1089/ars.2012.4795. Epub 2012 Oct 12. Review.

24.

Daunorubicin does not induce immunohistochemically detectable endothelial dysfunction in rabbit aorta and femoral artery.

Nachtigal P, Sterba M, Popelová O, Večeřová L, Kudláčková Z, Jirkovský E, Geršl V.

Histol Histopathol. 2011 May;26(5):551-62. doi: 10.14670/HH-26.551.

PMID:
21432770
25.

Proteomic insights into chronic anthracycline cardiotoxicity.

Stěrba M, Popelová O, Lenčo J, Fučíková A, Brčáková E, Mazurová Y, Jirkovský E, Simůnek T, Adamcová M, Mičuda S, Stulík J, Geršl V.

J Mol Cell Cardiol. 2011 May;50(5):849-62. doi: 10.1016/j.yjmcc.2011.01.018. Epub 2011 Jan 31.

PMID:
21284945
26.

In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity.

Vávrová A, Popelová O, Stěrba M, Jirkovský E, Hašková P, Mertlíková-Kaiserová H, Geršl V, Simůnek T.

Arch Toxicol. 2011 May;85(5):525-35. doi: 10.1007/s00204-010-0615-8. Epub 2010 Nov 3.

PMID:
21046361
27.

Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.

Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, Popelova O, Kalinowski DS, Kovarikova P, Vavrova K, Richardson DR, Simunek T.

Chem Res Toxicol. 2010 Jun 21;23(6):1105-14. doi: 10.1021/tx100125t.

PMID:
20521781
28.

Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits.

Adamcová M, Potáčová A, Popelová O, Stěrba M, Mazurová Y, Aupperle H, Geršl V.

Physiol Res. 2010;59(5):831-6. Epub 2010 Apr 20.

29.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA.

Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.

30.

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.

Popelová O, Sterba M, Hasková P, Simůnek T, Hroch M, Guncová I, Nachtigal P, Adamcová M, Gersl V, Mazurová Y.

Br J Cancer. 2009 Sep 1;101(5):792-802. doi: 10.1038/sj.bjc.6605192. Epub 2009 Jul 21.

31.

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.

Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V.

Pharmacol Rep. 2009 Jan-Feb;61(1):154-71. Review.

32.
33.

Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.

Simůnek T, Sterba M, Popelová O, Kaiserová H, Adamcová M, Hroch M, Hasková P, Ponka P, Gersl V.

Br J Pharmacol. 2008 Sep;155(1):138-48. doi: 10.1038/bjp.2008.236. Epub 2008 Jun 9.

34.

Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.

Popelová O, Sterba M, Simůnek T, Mazurová Y, Guncová I, Hroch M, Adamcová M, Gersl V.

J Pharmacol Exp Ther. 2008 Jul;326(1):259-69. doi: 10.1124/jpet.108.137604. Epub 2008 Apr 23.

PMID:
18434588
35.

Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.

Simunek T, Sterba M, Popelova O, Kaiserova H, Potacova A, Adamcova M, Mazurova Y, Ponka P, Gersl V.

Hemoglobin. 2008;32(1-2):207-15. doi: 10.1080/03630260701680276.

PMID:
18274998
36.

A pilot study of matrix metalloproteinases on the model of daunorubicin-induced cardiomyopathy in rabbits.

Potácová A, Adamcová M, Sterba M, Popelová O, Simůnek T, Mazurová Y, Guncová I, Gersl V.

Acta Medica (Hradec Kralove). 2007;50(2):109-11.

37.

New iron chelators in anthracycline-induced cardiotoxicity.

Kaiserová H, Simunek T, Sterba M, den Hartog GJ, Schröterová L, Popelová O, Gersl V, Kvasnicková E, Bast A.

Cardiovasc Toxicol. 2007;7(2):145-50. Review.

PMID:
17652820
38.

In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity.

Adamcová M, Šimůnek T, Kaiserová H, Popelová O, Štěrba M, Potáčová A, Vávrová J, Maláková J, Geršl V.

Toxicology. 2007 Jul 31;237(1-3):218-228. doi: 10.1016/j.tox.2007.05.016. Epub 2007 May 24.

PMID:
17587482
39.

Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents.

Potácová A, Adamcová M, Cajnáková H, Hrbatová L, Sterba M, Popelová O, Simůnek T, Ponka P, Gersl V.

Physiol Res. 2007;56(2):251-4.

40.

Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).

Sterba M, Popelová O, Simůnek T, Mazurová Y, Potácová A, Adamcová M, Guncová I, Kaiserová H, Palicka V, Ponka P, Gersl V.

Toxicology. 2007 Jun 25;235(3):150-66. Epub 2007 Mar 24.

PMID:
17459556
41.

Early detection of anthracycline cardiotoxicity in a rabbit model: left ventricle filling pattern versus troponin T determination.

Sterba M, Simůnek T, Popelová O, Potácová A, Adamcová M, Mazurová Y, Holecková M, Gersl V.

Physiol Res. 2007;56(5):535-45. Epub 2006 Dec 19.

42.

Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.

Sterba M, Popelová O, Simunek T, Mazurová Y, Potácová A, Adamcová M, Kaiserová H, Ponka P, Gersl V.

J Pharmacol Exp Ther. 2006 Dec;319(3):1336-47. Epub 2006 Sep 26.

PMID:
17003229
43.

HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study.

Kovaríková P, Klimes J, Sterba M, Popelová O, Gersl V, Ponka P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jul 11;838(2):107-12. Epub 2006 May 24.

PMID:
16725389
44.

Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits.

Sterba M, Simůnek T, Mazurová Y, Adamcová M, Popelová O, Kaplanova J, Ponka P, Gersl V.

Hum Exp Toxicol. 2005 Nov;24(11):581-9.

PMID:
16323575
45.

Myocardial regulatory proteins and heart failure.

Adamcová M, Stĕrba M, Simůnek T, Potácová A, Popelová O, Gersl V.

Eur J Heart Fail. 2006 Jun;8(4):333-42. Epub 2005 Nov 23. Review.

46.
47.

SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death.

Simůnek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, Gersl V, Hrdina R, Ponka P, de Lange JJ, Paulus WJ, Musters RJ.

J Mol Cell Cardiol. 2005 Aug;39(2):345-54.

PMID:
15978614
48.

Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits.

Simůnek T, Sterba M, Holecková M, Kaplanová J, Klimtová I, Adamcová M, Gersl V, Hrdina R.

Biometals. 2005 Apr;18(2):163-9.

PMID:
15954742
49.

Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity.

Adamcova M, Sterba M, Simunek T, Potacova A, Popelova O, Mazurova Y, Gersl V.

Expert Opin Drug Saf. 2005 May;4(3):457-72. Review.

PMID:
15934853
50.

Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.

Simůnek T, Klimtová I, Kaplanová J, Sterba M, Mazurová Y, Adamcová M, Hrdina R, Gersl V, Ponka P.

Pharmacol Res. 2005 Mar;51(3):223-31.

PMID:
15661572

Supplemental Content

Loading ...
Support Center